A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers.

Trial Profile

A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Temozolomide (Primary) ; Veliparib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
    • 25 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top